← Karyopharm Therapeutics Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $154k |
$1.6m
+942.21%
|
$30.3m
+1790.09%
|
$40.9m
+34.80%
|
$108.1m
+164.31%
|
$209.8m
+94.12%
|
$157.1m
-25.14%
|
$146.0m
-7.03%
|
$145.2m
-0.55%
|
$146.1m
+0.57%
|
$151.1m
+3.46%
|
|
| Research and Development Expense | $86.9m | $107.3m | $161.4m | $122.3m | $150.8m | $160.8m | $148.7m | $138.8m | $143.2m | $125.6m | $124.8m | |
| General and Administrative Expense | $23.9m | $24.9m | $48.8m | $105.4m | $126.4m | $143.8m | $145.4m | $131.9m | $115.4m | $105.2m | $104.5m | |
| Operating Lease, Expense | — | — | — | — | — | — | — | $2.8m | $2.8m | $2.4m | — | |
| Operating Costs and Expenses | — | — | — | $2.4m | $2.7m | $3.4m | — | — | — | — | — | |
| Operating Expenses | $110.9m | $132.1m | $210.2m | $230.2m | $279.9m | $308.1m | $299.3m | $275.6m | $264.7m | $236.8m | $235.3m | |
| Operating Income (Loss) | ($110.7m) |
($130.5m)
-17.89%
|
($179.9m)
-37.80%
|
($189.3m)
-5.22%
|
($171.8m)
+9.21%
|
($98.3m)
+42.82%
|
($142.2m)
-44.70%
|
($129.5m)
+8.90%
|
($119.4m)
+7.79%
|
($90.7m)
+24.06%
|
($84.2m)
+7.16%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | $10k | ($62k) | ($27k) | $100k | $300k | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | $10k | ($81k) | ($33k) | ($50k) | $206k | ($85k) | ($83k) | ($356k) | $28.4m | $152k | — | |
| Interest Expense (non-operating) | — | — | $2.5m | $15.6m | $27.1m | $26.0m | $25.0m | $23.8m | $37.4m | $45.8m | $47.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($82.5m) | ($93.2m) | ($149.7m) | ($176.2m) | ($158.9m) | ($93.8m) | ($165.8m) | ($143.0m) | ($76.4m) | ($192.4m) | ($195.0m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($109.4m) | ($128.9m) | ($178.4m) | ($199.6m) | ($196.0m) | ($123.8m) | ($164.9m) | ($142.8m) | ($76.4m) | ($196.0m) | ($195.0m) | |
| Income Tax Expense (Benefit) | $139k | $63k | $26k | $40k | $309k | $268k | $369k | $323k | $57k | $43k | $8k | |
| Net Income (Loss) Attributable to Parent | ($109.6m) |
($129.0m)
-17.71%
|
($178.4m)
-38.32%
|
($199.6m)
-11.87%
|
($196.3m)
+1.66%
|
($124.1m)
+36.78%
|
($165.3m)
-33.20%
|
($143.1m)
+13.43%
|
($76.4m)
+46.60%
|
($196.0m)
-156.52%
|
($195.0m)
+0.55%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($2.72) | ($1.65) | ($2.02) | ($1.25) | ($0.63) | ($17.93) | ($16.18) | |
| Earnings Per Share, Diluted | — | — | — | — | ($2.72) | ($1.65) | ($2.02) | ($1.25) | ($0.93) | ($17.93) | ($16.40) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 72.0m | 75.2m | 81.9m | 114.2m | 122k | 11k | 14.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 72.0m | 75.2m | 81.9m | 114.2m | 127k | 11k | 15.0m |